Introduction
============

iNOS inhibition in AHF is controversial, fuelled by conflicting results from studies using varieties of pharmacological agents, animal models and temporal protocols.

Methods
=======

We have previously described a robust model of acute hepatic and multi-organ failure in the Wistar rat. AHF was induced by two i.p. injections (500 mg/kg, 8 hours apart) of thioacetamide (TAA). Six groups were studied (*n* = 5). *Group 1* received TAA alone. *Groups 2, 3 & 4* followed protocol for *Group 1*, however, *Groups 2 & 3* were pre-treated and *Groups 4 & 5* post-TAA treated with iNOS inhibitors AMG (100 mg/kg s.c.) and L-NAME (100 mg/kg s.c.) for 5 days.

Results
=======

See Table

                                                                                                                                        Mortality
  ----------------- ------------ ---------------- ------------ ------------ ------------- ------------- --------------- --------------- -----------
  Hours             24           72               24           72           24            72            24              72              96
                                                                                                                                        
  G1, TAA           1653 ± 338   3166 ± 612       18 ± 3       121 ± 12     54 ± 12       169 ± 34      2.6 ± 0.8       5.26 ± 1        75
  G2, Pre-AMG       346 ± 102    1486 ± 341^\*^   32 ± 3^\*^   43 ± 7^\*^   47 ± 10^\*^   75 ± 14^\*^   1.9 ± 0.2^\*^   3.5 ± 0.4^\*^   10^\*^
  G3, Pre-L-Name    1780 ± 441   5179 ± 606^\*^   \>121^\*^    \>121        90 ± 10       151 ± 11      4.3 ± 0.3       6.5 ± 0.3       80
  G4, Post-AMG      2188 ± 450   5069 ± 512^\*^   \>121^\*^    \>121        132 ± 12      167 ± 8       3.3 ± 0.3       7.8 ± 0.6       100
  G5, Post-L-Name   1897 ± 327   5468 ± 268^\*^   \>121^\*^    \>121        139 ± 5       168 ± 9       4.2 ± 0.5       7.9 ± 0.5       100

^\*^*P* \< 0.05, mean ± SD.

Conclusion
==========

AMG is a more selective iNOS inhibitor, significantly reducing parameters of AHF compared L-NAME. Beneficial effects are, however, negated if iNOS inhibitors are administered after TAA, exacerbating hepatic injury, increasing mortality, and thus demonstrating temporal constraints.
